Myelodysplastic Syndrome Market - Forecast(2024 - 2030)
Overview
The global Myelodysplastic
Syndrome Market size is forecast to reach $2.69 billion by 2024, growing at a
CAGR of 9.68% during 2019-2024. Myelodysplastic syndrome is a condition where
immature cells in the bone marrow do not mature to become healthy blood cells.
Loss of a part of the long arm of chromosome 5 is a common chromosomal
abnormality seen in patients with myelodysplastic syndrome. With rise in the
overall geriatric population as well as with the growing awareness regarding
the disease the market is set to witness noteworthy growth in coming future.
Also, government initiatives such as reimbursement policies has the potential
to fuel overall market growth. Commonly used treatment
procedures for this disease are: stem cell transplantation and radiation
therapy.
Key Takeaways
- The North America region has been estimated to hold the largest share owing to the increased awareness as well as increased expenditure for health. Information on other major regions given in full myelodysplastic syndrome market report.
- The rise in the overall geriatric population globally is set to drive the market. Other major growth drivers mentioned in full myelodysplastic syndrome market report.
- The high treatment cost is considered as a challenge for the market growth. Other major challenges that has influence over the market mentioned in the full myelodysplastic syndrome market report.
Drug Class - Segment Analysis
The immunomodulatory drug class
is estimated to hold the largest share in this segment. This is a drug class
that is used in chemotherapy and is used for people with chromosomal
abnormalities. However, the Hypomethylating drugs segment is estimated to have
the largest CAGR of 8.64% during the forecast period owing to its increased
use.
Geography - Segment Analysis
The North America region has been
estimated to hold the dominance with myelodysplastic syndrome market share of
46.2%. This is owing to the high health expenditure cost as well as increased
awareness regarding the disease and the easy availability of treatment options.
However, the APAC region is estimated to have the highest CAGR during the
forecast period. This is due to the rapid urbanization of Asian Countries as
well as a rapid growth rate of the geriatric population. In the APAC region,
Japan is set to hold the highest growth rate.
Drivers – Myelodysplastic Syndrome Market
·
Rising Geriatric Population
There is an
overall increase in the geriatric population in the world. Studies has shown
that the prevalence of myelodysplastic syndrome increases in elderly population
and they are more likely to seek for treatment. This factor could be considered
as a major market driver.
·
Government
Support
The various
government initiatives that provide target specific treatment as well as
favorable reimbursement policies are estimated to fuel the overall
myelodysplastic syndrome market. The government initiatives can also rise the
overall awareness of the people.
Challenges – Myelodysplastic Syndrome Market
·
High
Treatment cost
The treatment for myelodysplastic
syndrome requires huge capital input. Also, other risks associated with the
treatment are present which can make the people reluctant to obtain the
treatment. This factor has the potential to limit the overall market growth.
Myelodysplastic Syndrome Industry Outlook
Partnerships and Product Launches are the key
strategies employed by the major players of this market. Myelodysplastic Syndrome top 10 companies include: Celgene
Corporation, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals
PLC, Johnson & Johnson, Lupin Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer,
Inc., Amgen Inc. and Takeda Pharmaceutical Company Limited., among others.
Partnerships/Product Launches
- On January 2015, Amgen and MD Anderson Cancer Center had announced an agreement for developing BiTE therapies for Myelodysplastic syndrome. This collaboration will call on the use of the MD Anderson Cancer Centre’s Moon Shots Program that aims to convert scientific discoveries into clinical advances at a much faster rate.
- On March 2017, Janssen-Cilag International N.V.(Johnson & Johnson) had announced that the product named “EPREX”for the treatment of symptomatic anemia for myelodysplastic syndrome has been approved for marketing by the French Authority Agence Nationale de Sécurité du Médicament et des Produits de Santé
1.1 Definitions and Scope
2. Myelodysplastic Syndrome Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Myelodysplastic Syndrome Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Myelodysplastic Syndrome Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Myelodysplastic Syndrome Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Myelodysplastic Syndrome Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Myelodysplastic Syndrome Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Myelodysplastic Syndrome Market - By Product (Market Size -$Million / $Billion)
8.1 Market Size and Market Share Analysis
8.2 Application Revenue and Trend Research
8.3 Product Segment Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
11. Myelodysplastic Syndrome- By Geography (Market Size -$Million / $Billion)
11.1 Myelodysplastic Syndrome Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Myelodysplastic Syndrome- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Myelodysplastic Syndrome- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Myelodysplastic Syndrome - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Myelodysplastic Syndrome - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Myelodysplastic Syndrome Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Myelodysplastic Syndrome Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Myelodysplastic Syndrome Market - Key Company List by Country Premium
16.1 Abbreviations
16.2 Sources
17. Myelodysplastic Syndrome Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends